This review assessed the frequency of heparin-induced thrombocytopenia (HIT) associated with venous thromboembolism in patients given unfractionated or low molecular weight heparin for thromboprophylaxis or treatment. The authors concluded that unfractionated but not low molecular weight heparin is associated with highfrequency HIT. Poor reporting, inadequate literature searches, failure to address study quality and inappropriate synthesis mean that the authors' conclusions are unlikely to be reliable.
To assess the frequency of heparin-induced thrombocytopenia (HIT) in patients presenting with venous thromboembolism (VTE) during or following heparin therapy for thromboprophylaxis or treatment.
Searching MEDLINE (November 1984 to November 2004 and the Cochrane Library (Issue 4, 2004) were searched. The search terms were reported and the MEDLINE search was restricted to RCTs. The text and bibliographies of summary articles, books and other related publications were screened, and personal files were reviewed. The review was limited to studies published in the English language.
Study selection
Study designs of evaluations included in the review Randomised controlled trials (RCTs) and prospective or retrospective cohort studies that enrolled consecutive patients were eligible for inclusion in the review.
Specific interventions included in the review
Studies of unfractionated heparin (UFH) or low molecular weight heparin (LMWH) used for prophylaxis or treatment were eligible for inclusion. The studies included in the review used both UFH and LMWH; UFH was administered either intravenously (IV) or subcutaneously, and LMWH (dalteparin, enoxaparin, fraxiparin and reviparin) subcutaneously. Some studies of acute VTE also administered a vitamin K antagonist in addition to heparin. Treatment duration was generally 7 to 10 days. Comparator study arms that administered selective factor Xa inhibitor fondaparinux were excluded. Some studies compared UFH with LMWH, while other studies only appeared to assess one form of heparin; it was unclear what treatment, if any, the comparator arms received in the latter studies.
Participants included in the review
Patients being treated or receiving prophylactic therapy for thrombosis were eligible for inclusion. Studies of both medical and surgical patients were included in the review. One study was conducted in a paediatric population; all other studies were conducted in adults. The studies included: patients with acute deep venous thrombosis or acute pulmonary embolism; medical patients, cardiac or neurological patients; patients who had undergone orthopaedic surgery or craniotomy; or paediatric intensive care patients.
Outcomes assessed in the review
The incidence of HIT associated with VTE, defined as an event that occurred in a patient with HIT, was the primary outcome included in the review. Studies were eligible for inclusion if they defined HIT, confirmed the diagnosis with laboratory testing, objectively documented new or recurrent VTE (deep venous thrombosis, pulmonary embolism or both), reported VTE for all patients and for patients with HIT, and at least one VTE occurred in the relevant study arms. The included studies typically defined HIT as a platelet count of <100 x10^9/L or a 40 to 50% decrease in count, with serologic confirmation. The duration of follow-up, where reported, ranged from 9 to 90 days.
